BACKGROUND: The aim of this study was to evaluate the impact of pathologic complete response (pCR) on outcome in patients with gastric or esophagogastric junction (EGJ) adenocarcinoma after neoadjuvant docetaxel/platin/fluoropyrimidine-based chemotherapy. PATIENTS AND METHODS: Patients received at least one cycle of chemotherapy for potentially operable disease. Pretreatment clinicopathologic factors and pCR were investigated. Disease-free survival (DFS), overall survival (OS) and tumor-related death were correlated with pCR. RESULTS: One hundred twenty patients were included in this analysis. Eighteen patients (15%) achieved a pCR. Tumor localization in the EGJ was identified as the only significant predictor of pCR (P = 0.019). Median follow-up was 41.1 months. Median DFS and OS for all patients were 24.1 and 48.6 months, respectively. Median DFS for patients with a pCR was not reached versus 22.1 months non-pCR patients (hazard ratio, HR 0.38; 3-year DFS: 71.8% and 37.7%, respectively, P = 0.018). While OS was not significantly different, the risk for tumor-related death was significantly lower for pCR patients compared with non-pCR patients (3-year cumulative incidences of 6.4% and 45.4%, respectively, P = 0.009). CONCLUSION: A pCR following preoperative docetaxel/platin/fluoropyrimidine indicates favorable outcome in patients with gastric or EGJ adenocarcinoma. Tumor location in the EGJ is associated with a higher pCR rate.
BACKGROUND: The aim of this study was to evaluate the impact of pathologic complete response (pCR) on outcome in patients with gastric or esophagogastric junction (EGJ) adenocarcinoma after neoadjuvant docetaxel/platin/fluoropyrimidine-based chemotherapy. PATIENTS AND METHODS: Patients received at least one cycle of chemotherapy for potentially operable disease. Pretreatment clinicopathologic factors and pCR were investigated. Disease-free survival (DFS), overall survival (OS) and tumor-related death were correlated with pCR. RESULTS: One hundred twenty patients were included in this analysis. Eighteen patients (15%) achieved a pCR. Tumor localization in the EGJ was identified as the only significant predictor of pCR (P = 0.019). Median follow-up was 41.1 months. Median DFS and OS for all patients were 24.1 and 48.6 months, respectively. Median DFS for patients with a pCR was not reached versus 22.1 months non-pCR patients (hazard ratio, HR 0.38; 3-year DFS: 71.8% and 37.7%, respectively, P = 0.018). While OS was not significantly different, the risk for tumor-related death was significantly lower for pCR patients compared with non-pCR patients (3-year cumulative incidences of 6.4% and 45.4%, respectively, P = 0.009). CONCLUSION: A pCR following preoperative docetaxel/platin/fluoropyrimidine indicates favorable outcome in patients with gastric or EGJ adenocarcinoma. Tumor location in the EGJ is associated with a higher pCR rate.
Authors: Michael J McNamara; David J Adelstein; Daniela S Allende; Joanna W Bodmann; Denise I Ives; Sudish C Murthy; Daniel Raymond; Siva Raja; Cristina P Rodriguez; Davendra Sohal; Kevin L Stephans; Gregory M M Videtic; Lisa A Rybicki Journal: J Gastrointest Cancer Date: 2017-06
Authors: M T Tetzlaff; J L Messina; J E Stein; X Xu; R N Amaria; C U Blank; B A van de Wiel; P M Ferguson; R V Rawson; M I Ross; A J Spillane; J E Gershenwald; R P M Saw; A C J van Akkooi; W J van Houdt; T C Mitchell; A M Menzies; G V Long; J A Wargo; M A Davies; V G Prieto; J M Taube; R A Scolyer Journal: Ann Oncol Date: 2018-08-01 Impact factor: 32.976
Authors: Jordan M Cloyd; Huamin Wang; Michael E Egger; Ching-Wei D Tzeng; Laura R Prakash; Anirban Maitra; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Michael J Overman; Eugene J Koay; Prajnan Das; Joseph M Herman; Michael P Kim; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: JAMA Surg Date: 2017-11-01 Impact factor: 14.766
Authors: Hironori Shiozaki; Rebecca S Slack; Hsiang-Chun Chen; Elena Elimova; Venkatram Planjery; Nick Charalampakis; Roopma Wadhwa; Yusuke Shimodaira; Heath Skinner; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela Blum-Murphy; Jane E Rogers; Dipen M Maru; Aurelio Matamoros; Tara Sagebiel; Jeannelyn S Estrella; Prajnan Das; Wayne L Hofstetter; Jeannette E Mares; Dilsa Mizrak Kaya; Kazuto Harada; Quan Lin; Bruce D Minsky; Brian D Badgwell; Jaffer A Ajani Journal: Oncology Date: 2016-04-28 Impact factor: 2.935
Authors: Michael J McNamara; Lisa A Rybicki; Davendra Sohal; Daniela S Allende; Gregory M M Videtic; Cristina P Rodriguez; Kevin L Stephans; Sudish C Murthy; Siva Raja; Daniel Raymond; Denise I Ives; Joanna W Bodmann; David J Adelstein Journal: J Gastrointest Oncol Date: 2016-04